Jesús F. San Miguel

Active 1948–2025

Also published as
Jesús-F San Miguel
500
Papers
108,960
Citations
158
h-index
484
i10-index

Citations

Citations per year for Jesús F. San Miguel1948: 5 citations1983: 3 citations1984: 2 citations1985: 8 citations1986: 11 citations1987: 8 citations1988: 14 citations1989: 10 citations1990: 13 citations1991: 5 citations1992: 16 citations1993: 10 citations1994: 12 citations1995: 12 citations1996: 13 citations1997: 21 citations1998: 42 citations1999: 75 citations2000: 91 citations2001: 131 citations2002: 141 citations2003: 210 citations2004: 202 citations2005: 213 citations2006: 286 citations2007: 321 citations2008: 463 citations2009: 564 citations2010: 623 citations2011: 688 citations2012: 615 citations2013: 715 citations2014: 721 citations2015: 736 citations2016: 812 citations2017: 799 citations2018: 679 citations2019: 3,007 citations2020: 3,379 citations2021: 3,568 citations2022: 2,828 citations2023: 2,196 citations2024: 4,055 citations2025: 1,729 citations2026: 50 citations1949–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,985 citing papers, 24.6% of this breakdownGermany: 1,690 citing papers, 6.9% of this breakdownItaly: 1,621 citing papers, 6.7% of this breakdownChina: 1,537 citing papers, 6.3% of this breakdownSpain: 1,487 citing papers, 6.1% of this breakdownUnited Kingdom: 1,461 citing papers, 6% of this breakdownFrance: 1,281 citing papers, 5.3% of this breakdownNetherlands: 886 citing papers, 3.6% of this breakdownCanada: 693 citing papers, 2.8% of this breakdownAustralia: 575 citing papers, 2.4% of this breakdownGreece: 532 citing papers, 2.2% of this breakdownJapan: 499 citing papers, 2% of this breakdown
0%24.6%Other 25.1%

Fields

  • Medicine74.1%
  • Biochemistry, Genetics and Molecular Biology16.8%
  • Immunology and Microbiology4.6%
  • Environmental Science1.4%
  • Computer Science0.5%
  • Engineering0.5%
  • Other2.1%

Topics

  • Multiple Myeloma Research and Treatments13.3%
  • Protein Degradation and Inhibitors5.4%
  • CAR-T cell therapy research4.5%
  • Acute Myeloid Leukemia Research3.5%
  • Lymphoma Diagnosis and Treatment3.3%
  • Chronic Lymphocytic Leukemia Research3.2%
  • Other66.8%

Coauthors

All papers

Open in search
  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 2,424

  2. Teclistamab in Relapsed or Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani - New England Journal of Medicine 2022 cited by 1,114

  3. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 cited by 2,995

  4. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 cited by 4,869

  5. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu‐Min Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele - New England Journal of Medicine 2023 cited by 733

  6. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  7. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Moreau - Journal of Clinical Oncology 2015 cited by 2,178

  8. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 820

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 cited by 407

  10. International Staging System for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2005 cited by 2,918

  11. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 178

  12. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 cited by 240

  13. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet 2021 cited by 312

  14. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 201

  15. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 1,034

  16. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn and 30 more - The Lancet 2019 cited by 636

  17. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Leukemia 2018 cited by 453

  18. International uniform response criteria for multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the International Myeloma Working Group - Leukemia 2006 cited by 2,639

  19. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian G.M. Durie, Jacques J. M. van Dongen, A Orfao - Leukemia 2017 cited by 657

  20. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 984

  21. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 1,434

  22. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 cited by 496

  23. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Blood 2018 cited by 495

  24. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 cited by 275